查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425113

Gabapentin市场 - 预测 2024-2029

Gabapentin Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

Gabapentin市场预计在预测期内复合年增长率为 3.82%。

口服Gabapentin溶液、锭剂和胶囊可与其他药物合併使用，帮助癫痫患者控制癫痫发作。带状疱疹后遗症神经痛(PHN) 的特征是带状疱疹爆发后持续数月至数年的烧灼样刺痛，可使用Gabapentin胶囊、锭剂和口服溶液治疗。Gabapentin喷丁缓释片（Horizo​​​​nt）用于治疗不宁腿症候群（RLS），这是一种导致腿部疼痛和强烈移动慾望的疾病，尤其是在夜间或坐着或躺着时。此外，Gabapentin透过减少过度活跃的大脑活动来治疗癫痫发作。

Gabapentin市场驱动因素

影响Gabapentin市场成长的主要因素是神经病变疼痛和癫痫发作的发生率增加以及疼痛管理药物的使用率增加。政府倡议的不断加强、製药公司的研发投资以及老年人口的增加是推动Gabapentin市场成长的主要因素。

增加疼痛管理的使用

Gabapentin用于缓解神经不适。普通药物通常无法缓解这种不适。Gabapentin改变神经与大脑的通讯方式。如果神经受到压迫或无法正常运作，它就会向大脑发送错误讯号。即使你身体的某个部位没有受伤，你的大脑还是会这样感知。Gabapentin透过改变神经功能来减轻疼痛。

Gabapentin新剂型的研发

抗惊厥药物Gabapentin用于治疗神经病变疼痛和局部癫痫发作，对Gabapentin市场的成长有正面影响。药物的药物动力学特性可以透过使用尼索姆（一种基于脂质的药物载体）来改善。在这项研究中，我们创建了Gabapentin的囊泡製剂，并评估了最佳囊泡製剂在正常细胞和结肠癌细胞株中的细胞毒性作用。我们创建了许多脂质体製剂并研究了它们的理化性质。 G3 和 G4 製剂的释放曲线与 Korsmeyer-Peppas 模型密切匹配，显示Gabapentin释放存在 Fickian 扩散机制。

扩大在医疗保健和诊所的使用

基层医疗医生、职业中期医生、神经科、内科医生和整形外科医生经常开立Gabapentin来治疗各种疾病。除了抗惊厥作用外，这种药物还有其他用途。护理师透过充当联络人、检查剂量和回答患者询问来为医生提供支援。专业团队的所有成员都知道Gabapentin滥用的可能性。这种专业团队合作可以最大限度地发挥Gabapentin治疗的益处，同时最大限度地减少潜在的副作用。因此，有关Gabapentin用的知识的增加正在推动Gabapentin市场的发展。

标籤仿单标示外治疗的使用增加

在医学领域，特别是在精神病学领域，Gabapentin经常在其核准用途之外使用。美国FDA 已就Gabapentin与中枢神经系统抑制剂 (CNS-D) 合併使用的危险发出警告，加巴喷丁经常被推荐用于精神科治疗。该警告的重点是在精神病学中同时使用中枢神经系统抑制剂（CNS-D）和Gabapentin的仿单标示外使用。

在北美，Gabapentin市场预计将稳定成长。

由于该地区神经系统疾病发病率高且以持续性疼痛为特征的疾病占主导地位，预计北美将占据Gabapentin市场的最大销售份额。 FDA 支持在这一领域推出学名药，这将增加该产品在美国的供应。此外，由于药品意识的提高，亚太地区预计将成为第二大成长产业。

併购

  • 2023 年4 月，GSK plc 和BELLUS Health Inc. 收购了BELLUS，这是一家加拿大后期生物製药公司，专注于改善难治性慢性咳嗽(RCC) 患者的生活，葛兰素史克为此支付了每股普通股14.75 美元现金。同意以约 20 亿美元（16 亿英镑）的股票收购该公司。
  • 2022年12月，JanOne收购了Soin Therapeutics及其LDN药物（现称为JAN123）。 JAN123是一种全新的双相LDN配方，含有2.0毫克LDN。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章Gabapentin市场：依类型

  • 介绍
  • 非专利的
  • 品牌

第六章Gabapentin市场：依应用分类

  • 介绍
  • 癫痫
  • 神经性疼痛
  • 不宁腿症候群
  • 其他的

第七章Gabapentin市场：依通路划分

  • 介绍
  • 医院药房
  • 零售药房
  • 其他的

第八章Gabapentin市场：按地区划分

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Pfizer
  • Fierce Pharma
  • Mayo Clinic
  • Ralington Pharma
  • Teva Pharmaceuticals
  • Gralise
  • Glenmark Pharmaceuticals
  • Stensa Lifesciences
  • Rosemont Pharmaceuticals
  • Lupin
简介目录
Product Code: KSI061616216

The gabapentin market is estimated to grow at a CAGR of 3.82% during the forecast period.

When used with other drugs, gabapentin oral solution, pills, and capsules assist individuals with epilepsy in controlling seizures. Additionally, postherpetic neuralgia (PHN), which is characterized by searing, stabbing pain or pains that can last for months or years following an outbreak of shingles, is treated with gabapentin capsules, tablets, and oral solutions. RLS, a disorder that causes pain in the legs and a strong impulse to move the legs, especially at night and when sitting or lying down, is treated with gabapentin extended-release tablets (Horizant). Further, Gabapentin cures seizures by reducing excessive brain activity.

Driving factors for the gabapentin market

The major factor influencing the growth of the gabapentin market is the increasing incidence of neuropathic pain and seizures and the rising utilization of pain management drug. Rise in government initiatives, R&D investments by pharmaceutical companies, and an increasing geriatric population are the key factors fueling the gabapentin market growth.

Increasing use for pain management

The medication gabapentin is used to relieve nerve discomfort. Typical medicines frequently fail to provide relief for this kind of discomfort. Gabapentin alters the way nerves communicate with the brain. A nerve can transmit erroneous signals to the brain when it is compressed or when it isn't functioning correctly in any other manner. Even when a portion of the body is not wounded, the brain perceives it as such. Gabapentin lessens the pain by changing the way nerves function.

Development of new formulations for Gabapentin

Anticonvulsant medication gabapentin is used to treat neuropathic pain and partial seizures and positively impacts the gabapentin market growth. The pharmacokinetic characteristics of medicinal medicines can be enhanced by the use of nisomes, a class of lipid-based drug carriers. In this work, a niosomal formulation of gabapentin was created, and the optimal niosomal formulation's cytotoxicity impact was assessed on normal cells and colon cancer cell lines. Numerous niosomal formulations were created, and the physicochemical characteristics of each were examined. The release profile for the G3 and G4 formulations closely matches the Korsmeyer-Peppas model and suggests the Fickian diffusion mechanism for gabapentin release.

Growing use in healthcare and clinics

Primary care physicians, mid-level practitioners, neurologists, internists, and orthopedic surgeons frequently prescribe gabapentin to treat a variety of medical conditions. In addition to its anti-seizure abilities, the medication has other applications. Nurses assist the physician by serving as a point of contact, reviewing doses, and responding to patient inquiries. The likelihood of gabapentin abuse is known to every member of the interprofessional team. The coordination of an interprofessional team in this way maximizes the benefits of gabapentin therapy while minimizing any possible side effects. This growing knowledge about the utilization is boosting the gabapentin market.

Increasing utilization in off-label medical practices

In medicine, especially psychiatry, gabapentin is frequently administered outside of its approved uses. The United States FDA issued a warning about the dangers of combining the medication gabapentin with central nervous system depressants (CNS-Ds), which are frequently recommended for psychiatric therapy. This focuses on concurrent CNS-D drug usage and off-label outpatient gabapentin use for psychiatric purposes.

In North America, it is projected that the gabapentin market will grow steadily.

North America is anticipated to hold the biggest revenue share in the gabapentin market owing to the high incidence of neurological diseases and ailments characterized by persistent pain in the area may be the reason for the dominance. The FDA is in favor of generic drug launches in the area, which will increase product availability in the United States. Furthermore, Asia Pacific is anticipated to be the second largest growing gabapentin industry, owing to the increase in awareness about the medications.

Merger & Acquisitions

  • In April 2023, GSK plc and BELLUS Health Inc. reached an agreement under which GSK will acquire BELLUS, a Canadian late-stage biopharmaceutical company that is working to improve the lives of patients with refractory chronic cough (RCC), for US$14.75 per share of common stock in cash, or roughly US$2.0 billion (£1.6 billion) in total equity value.
  • In December 2022, JanOne purchased Soin Therapeutics and its LDN medication, which is now known as JAN123, under the terms of the Purchase Agreement. JAN123 is a brand-new LDN formulation with a biphasic product release that contains 2.0 mg of LDN.

Market Key Developments

  • In September 2023, the leading global pharmaceutical company Lotus Pharmaceutical collaborated with the leading B2B pharma player, Adalvo, to announce the introduction of Gabapentin ER 300/600 mg in South Korea.
  • In March 2023, the pharmaceutical company Granules India Ltd. announced that the US health agency has approved its generic gabapentin pills for use in treating postherpetic neuralgia in adults. According to Granules India in a regulatory filing, the US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) for gabapentin tablets in the strengths of 600 mg and 800 mg.

Segmentation:

By Type

  • Generic
  • Branded

By Application

  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GABAPENTIN MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Generic
  • 5.3. Branded

6. GABAPENTIN MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Epilepsy
  • 6.3. Neuropathic Pain
  • 6.4. Restless Legs Syndrome
  • 6.5. Others

7. GABAPENTIN MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Others

8. GABAPENTIN MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Pfizer
  • 10.2. Fierce Pharma
  • 10.3. Mayo Clinic
  • 10.4. Ralington Pharma
  • 10.5. Teva Pharmaceuticals
  • 10.6. Gralise
  • 10.7. Glenmark Pharmaceuticals
  • 10.8. Stensa Lifesciences
  • 10.9. Rosemont Pharmaceuticals
  • 10.10. Lupin